Study wrapper · #1083
Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study.
AlTaweel MO, Al Makhloof S, AlKhayyal AK, et al. Expert review of cardiovascular therapy. 2026.
DOI: 10.1080/14779072.2026.2713476PubMed: 42535667
Editor's note
This small, single-center observational study examines semaglutide combined with an SGLT2 inhibitor and reports neutral, wide-confidence-interval results that the authors label exploratory. Outcomes were not independently adjudicated and the sample is limited, so no firm conclusion can be drawn about the combination. Regard the results as hypothesis-generating pending larger prospective trials.
Plain-language abstract
In a retrospective study of 376 adults, adding semaglutide to dapagliflozin was not significantly associated with different heart failure or heart attack outcomes, and early kidney function changes did not appear to explain any difference. The authors describe the findings as exploratory and hypothesis-generating.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026